Needham downgraded Clearside Biomedical (CLSD) to Hold from Buy with a $3 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical downgraded to Hold from Buy at JonesResearch
- Hold Rating for Clearside Biomedical Amid Strategic Uncertainty and Financial Constraints
- Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges
- Clearside Biomedical transitions all employees to consulting roles
- Clearside Biomedical to explore strategic alternatives to advance SCS platform